268 related articles for article (PubMed ID: 27544481)
1. Oxidative stress is increased in C. elegans models of Huntington's disease but does not contribute to polyglutamine toxicity phenotypes.
Machiela E; Dues DJ; Senchuk MM; Van Raamsdonk JM
Neurobiol Dis; 2016 Dec; 96():1-11. PubMed ID: 27544481
[TBL] [Abstract][Full Text] [Related]
2. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
[TBL] [Abstract][Full Text] [Related]
3. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
Bates EA; Victor M; Jones AK; Shi Y; Hart AC
J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant and neuroprotective effects of Dictyophora indusiata polysaccharide in Caenorhabditis elegans.
Zhang J; Shi R; Li H; Xiang Y; Xiao L; Hu M; Ma F; Ma CW; Huang Z
J Ethnopharmacol; 2016 Nov; 192():413-422. PubMed ID: 27647012
[TBL] [Abstract][Full Text] [Related]
5. Monascin from Monascus-Fermented Products Reduces Oxidative Stress and Amyloid-β Toxicity via DAF-16/FOXO in Caenorhabditis elegans.
Shi YC; Pan TM; Liao VH
J Agric Food Chem; 2016 Sep; 64(38):7114-20. PubMed ID: 27554775
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Therapeutic Targets for Polyglutamine Diseases That Target Mitochondrial Fragmentation.
Traa A; Machiela E; Rudich PD; Soo SK; Senchuk MM; Van Raamsdonk JM
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948242
[TBL] [Abstract][Full Text] [Related]
7. Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models.
Tauffenberger A; Chitramuthu BP; Bateman A; Bennett HP; Parker JA
Hum Mol Genet; 2013 Feb; 22(4):782-94. PubMed ID: 23172908
[TBL] [Abstract][Full Text] [Related]
8. Diphenyl diselenide protects a Caenorhabditis elegans model for Huntington's disease by activation of the antioxidant pathway and a decrease in protein aggregation.
Bicca Obetine Baptista F; Arantes LP; Machado ML; da Silva AF; Marafiga Cordeiro L; da Silveira TL; Soares FAA
Metallomics; 2020 Jul; 12(7):1142-1158. PubMed ID: 32453327
[TBL] [Abstract][Full Text] [Related]
9. A new Caenorhabditis elegans model of human huntingtin 513 aggregation and toxicity in body wall muscles.
Lee AL; Ung HM; Sands LP; Kikis EA
PLoS One; 2017; 12(3):e0173644. PubMed ID: 28282438
[TBL] [Abstract][Full Text] [Related]
10. Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection.
Kokona B; May CA; Cunningham NR; Richmond L; Jay Garcia F; Durante JC; Ulrich KM; Roberts CM; Link CD; Stafford WF; Laue TM; Fairman R
Protein Sci; 2016 Mar; 25(3):605-17. PubMed ID: 26647351
[TBL] [Abstract][Full Text] [Related]
11. The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington's disease.
Hernández IH; Torres-Peraza J; Santos-Galindo M; Ramos-Morón E; Fernández-Fernández MR; Pérez-Álvarez MJ; Miranda-Vizuete A; Lucas JJ
Acta Neuropathol; 2017 Dec; 134(6):839-850. PubMed ID: 28861715
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of the cultivated Chondrus crispus in a C. elegans model of Parkinson's disease.
Liu J; Banskota AH; Critchley AT; Hafting J; Prithiviraj B
Mar Drugs; 2015 Apr; 13(4):2250-66. PubMed ID: 25874922
[TBL] [Abstract][Full Text] [Related]
13. Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans.
Parker JA; Holbert S; Lambert E; Abderrahmane S; Néri C
J Mol Neurosci; 2004; 23(1-2):61-8. PubMed ID: 15126693
[TBL] [Abstract][Full Text] [Related]
14. Rutin protects Huntington's disease through the insulin/IGF1 (IIS) signaling pathway and autophagy activity: Study in Caenorhabditis elegans model.
Cordeiro LM; Machado ML; da Silva AF; Obetine Baptista FB; da Silveira TL; Soares FAA; Arantes LP
Food Chem Toxicol; 2020 Jul; 141():111323. PubMed ID: 32278002
[TBL] [Abstract][Full Text] [Related]
15. Insulin signaling and the heat shock response modulate protein homeostasis in the Caenorhabditis elegans intestine during infection.
Mohri-Shiomi A; Garsin DA
J Biol Chem; 2008 Jan; 283(1):194-201. PubMed ID: 17951251
[TBL] [Abstract][Full Text] [Related]
16. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
17. Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington's Disease.
Cong W; Bai R; Li YF; Wang L; Chen C
ACS Appl Mater Interfaces; 2019 Sep; 11(38):34725-34735. PubMed ID: 31479233
[TBL] [Abstract][Full Text] [Related]
18. PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.
Cherny RA; Ayton S; Finkelstein DI; Bush AI; McColl G; Massa SM
J Huntingtons Dis; 2012; 1(2):211-9. PubMed ID: 25063332
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells.
Oliveira AM; Cardoso SM; Ribeiro M; Seixas RS; Silva AM; Rego AC
Neurochem Int; 2015 Dec; 91():1-12. PubMed ID: 26476055
[TBL] [Abstract][Full Text] [Related]
20. Targeting Mitochondrial Network Disorganization is Protective in
Machiela E; Rudich PD; Traa A; Anglas U; Soo SK; Senchuk MM; Van Raamsdonk JM
Aging Dis; 2021 Oct; 12(7):1753-1772. PubMed ID: 34631219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
